References
- Creed R, Satyaprakash A, Tyring SK. Varicella Zoster Virus. In: Tyring SK, Yen Moore A and Lupi O (eds). Mucocutaneous Manifestations of Viral Diseases, 2ed, London: Informa Healthcare; 2010:98-122.
- Johnson RW, Bouhassira D, Kassianos G, Leplège A, Schmader KE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med 2010; 8:37; http://dx.doi.org/10.1186/1741-7015-8-37; PMID: 20565946
- Zostavax (zoster vaccine, live) [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2009. Available at: http://www.merck.com/product/usa/pi_circulars/z/zostavax/zostavax_pi2.pdf. Accessed 31-May-2011.
- Centers for Disease Control and Prevention. Prevention of herpes zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2008; 57:1 - 5; PMID: 18185492
- National Health & Medical Research Council. The Australian immunisation handbook. Williams A, ed. Canberra: Australian Government Publishing Service, 2008.
- EMEA Committee for Medicinal Products for Human Use. Product information for ZOSTAVAX™. http://www.emea.europa.eu/humandocs/PDFs/EPAR/zostavax/H-674-PI-en.pdf. Accessed 27-Mar-2009.
- Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271 - 84; http://dx.doi.org/10.1056/NEJMoa051016; PMID: 15930418
- Simberkoff MS, Arbeit RD, Johnson GR, Oxman MN, Boardman KD, Williams HM, et al. Safety of Zoster Vaccine in the Shingles Prevention Study: A Randomized Trial. Ann Intern Med 2010; 152:545 - 54; PMID: 20439572
- Levin MJ, Oxman MN, Bobrove AM, Hayden FG, Hayward AR, Irwin M, et al. Dose ranging safety and immunogenicity study of live attenuated Varicella-Zoster virus (VZV) vaccine (Oka/Merck) administered to adults 60 years of age or older: GER-3. South Med J 2005; 98:S55; http://dx.doi.org/10.1097/00007611-200510001-00151
- Schmader KE, Bobrove AM, Levin MJ, Oxman M, Tucker R, Reisinger K, et al. Immunogenicity & Safety of Varicella-Zoster Virus (VZV) Vaccine Administered to Older Adults With or Without Diabetes Mellitus (DM) or Chronic Obstructive Pulmonary Disease (COPD). In: Program and abstracts of the Annual Scientific Meeting of the American Geriatrics Society; May 5, 2006; Chicago, IL. Abstract #227638.
- Macaladad N, Marcano T, Guzman M, Moya J, Jurado F, Thompson M, et al. Safety and immunogenicity of a high-potency zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults. Vaccine 2007; 25:2139 - 44; http://dx.doi.org/10.1016/j.vaccine.2006.11.011; PMID: 17250932
- Lange J, Tyring SK, Peters PH, Nunez M, Poland G, Levin MJ, et al. Immunogenicity, Kinetics of VZV-Specific CD4+ T-cell γ-IFN Production and Safety of a Live Attenuated Oka/Merck Zoster Vaccine in Healthy Adults ≥ 60 Years of Age. In: Program and abstracts of the 44th Annual Meeting if the Infectious Diseases Society of America; October 12-15, 2006; Toronto, Canada. Abstract #857.
- Tyring SK, Diaz-Mitoma F, Padget LG, Nunez M, Poland G, Cassidy WM, et al. Safety and tolerability of a high-potency zoster vaccine in adults >/=50 years of age. Vaccine 2007; 25:1877 - 83; http://dx.doi.org/10.1016/j.vaccine.2006.10.027; PMID: 17227688
- Gilderman LI, Lawless JF, Nolen TM, Sterling T, Rutledge RZ, Fernsler DA, et al. A Double-Blind, Randomized, Controlled, Multicenter Safety and Immunogenicity Study of a Refrigerator-Stable Formulation of ZOSTAVAX®. [Comment in: Clin Vaccine Immunol. 2009;16:1381; author reply 1381-2] Clin Vaccine Immunol 2008; 15:314 - 9; http://dx.doi.org/10.1128/CVI.00310-07; PMID: 18077611
- Kerzner B, Murray AV, Cheng E, Ifle R, Harvey PR, Tomlinson M, et al. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc 2007; 55:1499 - 507; http://dx.doi.org/10.1111/j.1532-5415.2007.01397.x; PMID: 17908055
- MacIntyre CR, Egerton T, McCaughey M, Parrino J, Campbell BV, Su SC, et al. Concomitant Administration of Zoster and Pneumococcal Vaccines in Adults ≥60 Years Old. Hum Vaccin 2010; 6:894 - 902; http://dx.doi.org/10.4161/hv.6.11.12852; PMID: 20980796
- Mills R, Tyring SK, Levin MJ, Parrino J, Li X, Coll KE, et al. Safety, Tolerability, and Immunogenicity of Zoster Vaccine in Subjects With a History of Herpes Zoster (HZ). Vaccine 2010; 28:4204 - 9; http://dx.doi.org/10.1016/j.vaccine.2010.04.003; PMID: 20416263
- Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4:213 - 26; http://dx.doi.org/10.1002/sim.4780040211; PMID: 4023479